1122 related articles for article (PubMed ID: 17583395)
1. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
[TBL] [Abstract][Full Text] [Related]
2. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
[TBL] [Abstract][Full Text] [Related]
3. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
[TBL] [Abstract][Full Text] [Related]
4. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
[TBL] [Abstract][Full Text] [Related]
5. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases
Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
[TBL] [Abstract][Full Text] [Related]
6. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.
Mertsola J; Van Der Meeren O; He Q; Linko-Parvinen A; Ramakrishnan G; Mannermaa L; Soila M; Pulkkinen M; Jacquet JM
Clin Infect Dis; 2010 Sep; 51(6):656-62. PubMed ID: 20704493
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
[TBL] [Abstract][Full Text] [Related]
8. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
[TBL] [Abstract][Full Text] [Related]
9. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
McCormack PL
Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
[TBL] [Abstract][Full Text] [Related]
10. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
[TBL] [Abstract][Full Text] [Related]
12. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.
McIntyre PB; Turnbull FM; Egan AM; Burgess MA; Wolter JM; Schuerman LM
Vaccine; 2004 Dec; 23(3):380-5. PubMed ID: 15530684
[TBL] [Abstract][Full Text] [Related]
13. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials.
Van Damme P; McIntyre P; Grimprel E; Kuriyakose S; Jacquet JM; Hardt K; Messier M; Van Der Meeren O
Vaccine; 2011 Aug; 29(35):5932-9. PubMed ID: 21718738
[TBL] [Abstract][Full Text] [Related]
15. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine.
Weston W; Messier M; Friedland LR; Wu X; Howe B
Vaccine; 2011 Nov; 29(47):8483-6. PubMed ID: 21945698
[TBL] [Abstract][Full Text] [Related]
16. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
[TBL] [Abstract][Full Text] [Related]
17. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
[TBL] [Abstract][Full Text] [Related]
18. Booster vaccination of toddlers with reduced antigen content diphtheria -- tetanus -- acellular pertussis vaccine.
Nolan T; Ruff TA; Lambert SB; Buttery J; O'Grady KA; Streeton C; Hoet B; Bock HL
Vaccine; 2009 Apr; 27(18):2410-3. PubMed ID: 19368781
[TBL] [Abstract][Full Text] [Related]
19. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?
Halperin SA; Sweet L; Baxendale D; Neatby A; Rykers P; Smith B; Zelman M; Maus D; Lavigne P; Decker MD
Pediatr Infect Dis J; 2006 Mar; 25(3):195-200. PubMed ID: 16511379
[TBL] [Abstract][Full Text] [Related]
20. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.
Halperin SA; Donovan C; Marshall GS; Pool V; Decker MD; Johnson DR; Greenberg DP;
J Pediatric Infect Dis Soc; 2019 May; 8(2):105-114. PubMed ID: 29438562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]